Aberrant Expression TFR1/CD71 in Gastric Cancer Identifies a Novel Potential Prognostic Marker and Therapeutic Target

Table 2

Correlation of TFR1 expression and clinicopathological characteristics.

Variables		TFR1 expression		Total	X2	value
		Positive	Negative
Age (y)
	≥60	67	25	92	10.146
	<60	30	33	63
Gender
	Male	74	39	113	1.907	0.167
	Female	23	20	43
Location
	Proximal	35	13	48	4.413	0.110
	Distal	54	42	96
	Total	8	3	11
Lauren type
	Intestinal type	55	19	74	11.821
	Diffuse type	28	27	55
	Mixed type	14	10	24
	Unknown	0	2	2
Borrmann type
	I + II	50	39	89	4.118	0.128
	III + IV	46	18	64
	Unknown	1	1	2
Differentiated degree
	Well/moderate	21	6	27	3.225	0.073
	Moderate-poor/poor	76	52	128
T stage
	T1+2	1	7	8	9.035
	T3+4	96	51	147
N stage
	N0+N1	23	19	42	1.504	0.220
	N2+N3	74	39	113
M stage
	M0	86	54	140	0.820	0.365
	M1	11	4	15
TNM stage
	I + II	9	11	20	3.031	0.082
	III + IV	88	47	135
HER2
	Positive	17	1	18	8.830
	Negative	80	57	137
PD-L1
	Positive	46	8	54	18.083
	Negative	51	50	101
CEA
	Positive	30	10	40	3.551	0.060
	Negative	67	48	115
CA125
	Positive	10	3	13	0.668	0.414
	Negative	87	55	142
CA72-4
	Positive	24	6	30	4.820
	Negative	73	52	125
AFP
	Positive	8	0	8	3.500	0.061
	Negative	89	58	147
CA19-9
	Positive	35	16	51	1.187	0.276
	Negative	62	42	104